News

Explore Latest News .

Find all the latest news on Paul Peter Tak, as well as a comprehensive list of his past interviews and features. Paul Peter’s work in immunology and the pharmaceutical industry has led him to be featured in both business and medicine specific publications.

During his time at GlaxoSmithKline, Paul Peter gave a number of interviews and briefs, including one with the Biochemical Society in 2017. In this insightful interview, Paul Peter outlined what the GSK Immunology Network was and its impact on this important area of research.

In December 2020, Paul Peter Tak spoke with Eleanor Malone, from Scrip, about the work Candel Therapeutics was undertaking in the field of cancer immunotherapy and the companies ambitious future. Paul Peter has also had more broad discussions around his career and what inspires him, such as his interview with Stephanie Sutton for The Medicine Maker, in 2020.   

Ignition of a new era of cancer treatments

Candel’s CEO looks to help ignite a new era of cancer treatments | PharmaVoice

Empowered Patient Podcast: Developing Immunotherapies Using Oncolytic Viruses to Change the Tumor Microenvironment

https://empoweredpatientradio.com/developing-immunotherapies-using-oncolytic-viruses-to-change-the-tumor-microenvironment-with-dr-paul-peter-tak-candel-therapeutics

Pillars of success for building an innovative organisation

Embark on a transformative journey with Dr. Paul Peter Tak as he unravels the “Pillars of Success for Building an Innovative Organization” in this enlightening video. As a seasoned leader in the bio…

The Netherlands: ‘Boston by the North Sea?’

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-…

A glorious moment, knowing that we have secured the proceeds to deliver on our mission to develop better medicines for patients

Paul Peter Tak

© Paul Peter Tak.
All rights reserved.